February 20, 2019 This article originally appeared on ONA. Share this content: Older men with metastatic castration-resistant prostate cancer are often perceived as likely to play a passive role regarding care-related decisions. A survey of Dutch multidisciplinary healthcare providers on the use of ...

February 16, 2019 Share this content: Obese men treated with docetaxel for metastatic castration-resistant prostate cancer have longer cancer-specific and overall survival, a study found. SAN FRANCISCO—Obesity is associated with improved cancer-specific and overall survival among men with metastat...

Copyright © 2018 Haymarket Media, Inc. All Rights ReservedThis material may not be published, broadcast, rewritten or redistributed in any form without prior authorization.Your use of this website constitutes acceptance of Haymarket Media’s Privacy Policy and Terms & Conditions....

Copyright © 2018 Haymarket Media, Inc. All Rights ReservedThis material may not be published, broadcast, rewritten or redistributed in any form without prior authorization.Your use of this website constitutes acceptance of Haymarket Media’s Privacy Policy and Terms & Conditions....

February 15, 2019 This article originally appeared on Cancer Therapy Advisor. Share this content: By targeting prostate-specific membrane antigen, a molecule radiolabeled with lutetium-177 is expected to deliver high doses of beta radiation to distant metastases. SAN FRANCISCO — Treatment with a n...

February 15, 2019 This article originally appeared on Cancer Therapy Advisor. Share this content: After an additional 1 year of follow-up, apalutamide plus ADT continued to show a significant decrease in the risk of progression to metastasis or death. An updated analysis of patients in the SPARTAN t...

February 15, 2019 This article originally appeared on Cancer Therapy Advisor. Share this content: The Decipher genomic classifier predicted metastases and prostate cancer-specific mortality following radical prostatectomy with greater precision in African-American men. SAN FRANCISCO — Decipher, a ...

February 15, 2019 This article originally appeared on Cancer Therapy Advisor. Share this content: The study is the first to show that treatment with abiraterone acetate/enzalutamide is associated with better survival in African American patients with mCRPC compared with Caucasians. SAN FRANCISCO —...

February 14, 2019 Share this content: Median metastasis-free survival was longer with darolutamide than with placebo: 40.4 vs 18.4 months. Darolutamide, a new androgen-receptor antagonist, prolongs survival without metastases in men with nonmetastatic castration-resistant prostate cancer (CRPC) and ...

February 14, 2019 Share this content: In a “real world” study, biopsy and surgical grade groups 2, 3, 4, and 5 each were associated with incrementally higher risks for adverse pathologic features and biochemical recurrence. The Grade Group system (GG) introduced in 2013 improves prediction of pa...